Kornimate/medical-research-clean huggingface dataset:
insync iii marquis model 7279 cardioverter defibrillator cardiac resynchronization system

Conditions: Heart Failure

Summary: people who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (icd). an icd is implanted surgically just under the skin in the upper chest area and it sends a strong electrical impulse, or shock, to the heart to return it to a normal rhythm. if the heart is beating too slowly or at an abnormal rhythm, an icd can also pace the heart to return the heart to its normal rhythm. the insync iii marquis device can change the timing of when the left and right ventricles of the heart are paced to beat. this is called "v to v timing". v to v timing may further improve the pumping function of the heart. the purpose of this study is to determine whether or not this v to v timing feature of the insync iii marquis system is safe and effective.


Eligibility criteria:
inclusion criteria: subject has, or is at risk of having, a heart beat that is too fast and his/her doctor has determined the need for an implantable cardioverter defibrillator. subject is on optimal medical treatment for heart failure. subject has reduced left ventricular ejection fraction (lvef≤35%). (lvef is a measurement of how well the left ventricle pumps blood out to the rest of the body. the higher the lvef the more blood the ventricle is pumping.) subject who has heart failure which severely limits daily activities (nyha class iii) or subject who has severe heart failure and should always be resting (nyha class iv) subject who has a qrs≥130ms (the qrs interval is a measurement of how the electrical signal involved in a heart beat travels/conducts through the ventricles. a wide qrs (more than 120 ms) suggests that there is a conduction problem (or block) in the ventricles.) subjects with a left ventricular end diastolic dimension (lvedd≥55mm). (the lvedd is a measurement taken during an echocardiogram that is one indication of the health of the left ventricle.) exclusion criteria: subject has unstable chest pain, heart surgery within past 3 months subject has liver function tests greater than 3 times normal limits subject has chronic (permanent) atrial arrhythmias (fast heart beats in the upper chamber(s) of the heart)

Keywords: heart failure, cardiac resynchronization
a study of evaluating the efficacy and safety of shr4640 in subjects with gout

Conditions: Gout

Summary: this study will assess the serum uric acid lowering effects and safety of shr4640 compared to placebo and allopurinol in patients with gout


Eligibility criteria:
inclusion criteria: 1. subject who met 1977 or 2015 acr (american college of rheumatology) classification of gout and has a serum acid ≥ 480 μmol/l at screening; 2. 18 kg/m2 ≤body mass index (bmi)≤ 35 kg/m2 exclusion criteria: 1. subject who is pregnant or breastfeeding; 2. alanine aminotransferase or aspartate aminotransferase or total bilirubin\>1.5 upper normal limit; 3. subject with a positive test for hla-b\*5801; 4. estimated glomerular filtration rate (mdrd formula) \<60ml/min; 5. hba1c\>8%; 6. subject with known hypersensitivity or allergy to shr4640 and allopurinal, or any component of shr4640; 7. subject with kidney stones or suspicion of kidney stones; 8. subject who has acute gout flares within 2 weeks before randomization; 9. subject with a history of malignancy within the previous 5 years; 10. subject with a history of active peptic ulcer within a year; 11. subject with a history of xanthine urine.
antithrombin iii in infectious disease caused by covid-19

Conditions: Antithrombin III Deficiency; Covid19

Summary: the purpose of this research study is to see if participants who have sars-cov-2 and low levels of at3 in the blood will benefit by being given at3.


Eligibility criteria:
inclusion criteria: 1. \>18y of age, 2. subject or proxy who can provide informed consent 3. positive sars-cov-2 by polymerase chain reaction (pcr) or as determined by clinical team exclusion criteria: 1. adults or proxy unable to consent 2. individuals who are not yet adults (infants, children, teenagers) 3. pregnant women 4. prisoners 5. patients expected to die within 24 hours or with a "do not resuscitate" order, 6. multi-organ failure, 7. history of hypersensitivity or allergy to any component of the study drug, 8. ongoing massive surgical or unexplained bleeding, 9. history of bleeding or clotting disorder, 10. severe traumatic brain injury (glasgow coma scale \<6), 11. spinal or multiple-trauma, 12. cancer (incurable/terminal phase) and/or patients receiving palliative care, 13. enrollment in another concurrent clinical interventional study if considered interfering with this study objectives 14. per study team discretion, any condition(s) that may prevent safe treatment, preclude adequate evaluation or adding further risk to their underlying illness.
severe sepsis and septic shock registry

Conditions: Sepsis

Summary: the aim of this study is to construct multi-center sepsis registry that can be used for data warehousing and clinical research.

this registry prospectively enrolls adult patients with severe sepsis or septic shock in 21 tertiary hospital emergency departments. registered data can be used for quality control and clinical research to reduce sepsis-related mortality.

Eligibility criteria:
inclusion criteria: * two of more systemic inflammatory reaction syndrome criteria fever \> 38.3 'c or hypothermia \< 36'c, tachycardia over 90 bpm tachypnea over 20 per minute, leukocytosis (wbc over 12k/microl) or leukopenia (wbc below 4k/microl) * suspected or proven infection * any organ dysfunction as follows: 1. cardiovascular (hypotension, systolic blood pressure \<90 mmhg, mean arterial pressure \<70mmhg) 2. tissue hypoperfusion (lactate above upper limits laboratory normal) 3. acute lung injury (pao2/inspired oxygen fraction \< 250 in the absence of pneumonia, pao2/inspired oxygen fraction \< 200 in the presence of pneumonia) 4. acute kidney injury (urine output \ 2.0 mg/dl) 5. acute liver injury (total bilirubin \> 2mg/dl) 6. acute coagulopathy (platelet count \ 1.5) exclusion criteria: * age less than 18 years old * patients with cardiac arrest at presentation * patients with advanced directives not to deliver aggressive organ supportive management
diabetic foot ulcer research study

Conditions: Diabetic Foot Ulcer; Diabetic Foot Ulcer Neuropathic; Diabetic Foot Ulcer Ischemic

Summary: the goal of this clinical trial is to compare safety and performance of the study device to the current typical nhs standards of care device. the main outcomes it aims to achieve are: complete wound healing at 12 weeks (100% epithelialised) % reduction in wound area at 12 weeks participants will attend their nhs podiatry clinic appointment as normal and will be assigned either the study device or the current typical nhs standard of care device. researchers will compare the study device group to the standard group to assess the outcomes mentioned previously.

the purpose of this clinical trial is to evaluate the safety and performance of the rtd wound dressing in the treatment of non-infected neuropathic, ischaemic, and neuro-ischaemic diabetic foot ulcers versus standard of care. this clinical evaluation study will be performed under an open-label, comparative, design in the single health board of nhs lanarkshire within 3 diabetic foot clinics.

Eligibility criteria:
inclusion criteria: * male or female, aged ≥18 years old with a diagnosis of type 1 or type 2 diabetes. * new presentation for treatment of a neuropathic, ischaemic or neuro- ischaemic non- infected dfu * subjects must be able to follow verbal and written instructions in english * subjects must have full mental capacity and able to give written informed consent to participation in the trial including medical photography for the purposes of the clinical trial or clinical care. * dfu is \>10mm2 and \<100mm2 exclusion criteria: * known allergy/hypersensitivity to any ingredient contained in the keneric healthcare rtd wound dressing * participants who will have problems following the protocol, including the offloading system, provided as standard of care, to wear on a daily basis * suspected malignancy in the wound * critical limb ischaemia * pregnant or breastfeeding females * women of childbearing potential and not using a medically accepted form of contraception when sexually active.

Keywords: diabetes foot ulcer diabetic foot ulcer
impact of mindful self-compassion therapy on self harm behaviors, emotional regulation and quality of life among patients with borderline personality disorder

Conditions: Psychological Distress; Emotional Regulation; Self Harm; Quality of Life (QOL); Borderline Personality Disorder (BPD)

Summary: the primary purpose of the study is to investigate whether mindful self-compassion (msc) therapy can significantly reduce self-harm behaviors, improve emotional regulation, and enhance the quality of life in individuals diagnosed with borderline personality disorder (bpd). the study aims to contribute to the existing literature by providing robust evidence on the efficacy of msc therapy for bpd, which could inform clinical practices and improve treatment outcomes

the current quantitative study will be carried out in two phases. a cross-sectional survey will assess quality of life, emotional regulation, psychological distress, self-harm behaviors, social support, and state of mindfulness during the first phase. a randomized controlled trial (rct) will be done during the second phase where patients with borderline personality disorder who are identified with psychological distress, low level of social support, and quality of life, will be categorized into two groups i.e. waitlist control group and intervention group through the process of randomization. then mindful self compassion therapy would be applied to participants in the intervention group. the control group is the waitlist control group so initially no intervention will be given to participants in the control group but the intervention will be given to the control group participants once the study is completed. the mindful self compassion therapy would be implemented on participants using individual and in-person modes. the pre-and post-assessment will be done at times 1 and 2 within and between control and interventional groups. after doing post-assessment the difference between pre and post-assessment will be compared to explore the efficacy of mindful self compassion therapy in patients with borderline personality.

Eligibility criteria:
inclusion criteria: * 1. first time diagnosed non-hospitalized patients of borderline personality disorder. 2. patients of borderline personality disorder experiencing psychological distress,low level of quality of life, social support, emotional dysregulation would be included. 3. borderline personality disorder patients with age 18 years and above (both gender) from outpatient department (opd) 4. borderline personality patients who would be able to understand urdu language and can give the informed consent * exclusion criteria the study would have the following exclusion criteria: 1. hospitalized patients of borderline personality 2. patients with borderline personality having other chronic co-morbid diseases such as cancer, cognitive deficits, and other chronic psychological disorders. 3. patients with borderline personality younger than 18 years of age
prevention of infection in closed fractures: cefazolin versus vancomycin

Conditions: Infection; Closed Fractures

Summary: the purpose of this study is to compare the incidence rate of infection in surgical patients with closed fractures treated prophylactically with cefazolin versus vancomycin in the peri-operative period. the hypothesis of this study is that patients undergoing surgical treatment for closed fractures who are treated prophylactically with vancomycin will have a lower incidence rate of infection than patients who are treated prophylactically with cefazolin.


Eligibility criteria:
inclusion criteria: * between 18 years old and 85 years old * closed fracture * fracture treatment plan is for one operation on one day (one surgical setting) * likely to follow-up with surgeon until fracture is healed * ability to understand and agree to informed consent exclusion criteria: * under 18 years old or over 85 years old * open fracture(s) * fracture requires multiple operations * other injuries requiring operations * documented allergy to cefazolin or vancomycin * previous history of methicillin-resistant staphylococcus aureus infection * previous surgery on the injured extremity within 1 year * use of antibiotics within 2 weeks before or after injury * use of antibiotics within 2 weeks before surgery * unlikely to follow-up until fracture is healed * unable to understand and agree to informed consent
daptomycin vs. vancomycin for the treatment of methicillin resistant s. aureus bacteremia

Conditions: Staphylococcus Aureus Septicemia; Staphylococcus Aureus Bacteremia; S. Aureus Bacteremia; S. Aureus Bloodstream Infection; Staphylococcus Aureus Endocarditis

Summary: this is an open label randomized controlled trial for patients with methicillin resistant s. aureus (mrsa) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. this study is an approved sub-study of the staphylococcus aureus network adaptive platform (snap) trial (nct05137119)


Eligibility criteria:
the participant must meet all inclusion and exclusion criteria for the snap platform (nct05137119) and also the following inclusion and exclusion criteria: inclusion criteria: * methicillin-resistant s. aureus bacteremia exclusion criteria: * severe allergy or non-severe rash to vancomycin or daptomycin * suspected or confirmed mrsa pneumonia * known vancomycin minimum inhibitory concentration (mic) greater than or equal to 2mg/l or daptomycin mic greater than or equal to 1mg/l

Keywords: s. aureus bacteremia methicllin resistant mrsa s. aureus bloodstream infection daptomycin vancomycin
functional and neuroplastic effects of habit-ile in children with bilateral cerebral palsy

Conditions: Cerebral Palsy

Summary: this randomized controlled trial will compare the effects of neuroplastic and functional changes of hand-arm bimanual intensive therapy including lower extremities (habit-ile) when presented in two periods (2hg; n=24) versus a single period (1hg; n=24) in people with bilateral cp. the 1hg will receive 65 hours of habit-ile over one intervention period; the 2hg will receive 130 hours over two intervention periods, within 6 months apart. children will be assessed at 6 time points: baseline, three weeks after the start, at 3, 6, 7 and 9 months after the start of the study.

this study aims to compare, for the first time, the effects of a double period of habit-ile therapy on functional and neuroplastic changes against a single period, in people with bilateral cerebral palsy (cp). previous habit-ile protocols have only assessed the effects of a single intervention period. still, the literature suggests a possible dose-response relationship between the number of intensive therapy periods and progress in motor function. a randomized controlled trial will be conducted, comparing the effects of a double period of habit-ile; (2hg; n=24) versus a single period (1hg; n=24) in children and youth with bilateral cp. each habit-ile period will consider 6.5 hours of intervention during 10 consecutive working days. children will be assessed at 6-time points: baseline, three weeks after, at 3 months, at 6 months, at 7 months, and at 9 months, to evaluate the long-term effect of habit-ile and the summative effects of the double period in functional and neuroplastic variables. the 1hg will receive only 65 hours of habit-ile after baseline; the 2hg will perform 130 hours over two intervention periods, after baseline and again at 6 months. overall, this study aims to provide evidence for the effectiveness of habit-ile in producing functional and neuroplastic changes in children with bilateral cp. it will allow us to approach the possible mechanisms underlying the effect of habit-ile.

Eligibility criteria:
inclusion criteria: * children with medical diagnosis of bilateral cerebral palsy * cognitive capacity and language that allows understanding and following the therapist's instructions. * manual ability classification system (macs) levels i to iii * bimanual fine motor function (bfmf) levels i to iii * gross motor function classification system (gmfcs) levels i to iii exclusion criteria: * severe visual problems * movement restriction due to orthopedic surgery in less than a year * treatment with botulinum toxin and/or baclofen pump in the last 6 months * contraindications to receive transcranial magnetic stimulation (epileptic history, metallic implants, neoplasm, etc.)

Keywords: habit-ile intensive motor therapy motor skill learning children
miller straight blade vs macintosh blade

Conditions: Intubation; Difficult

Summary: the purpose of this prospective open labeled randomized study was to compare the "laryngoscopic glottis view" as well as "ease of intubation" between the two blades in routine intubations in non-difficult airways.

one hundred and fifty patients with predicted non difficult airway were randomly assigned into two groups. after induction of anaesthesia laryngoscopy was performed with respective blades and trachea intubated. parameters monitored were: glottis view obtained during laryngoscopy (cormack lehane grade), ease of intubation, intubation attempts, total duration of laryngoscopy in seconds and encountered complications.

Eligibility criteria:
inclusion criteria: * all asa i \& ii grade patients undergoing elective surgery requiring general anesthesia with oral endotracheal intubation exclusion criteria: * patients with anticipated difficult airway * cervical spine disorders * anesthesia requiring rapid sequence induction
coral xt - open-label extension trial of the coral trial

Conditions: Pain; Neoplasms; Chronic Pain

Summary: the purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. in addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.

the trial consisted of 3 phases: titration phase, maintenance phase, and follow-up. the total duration of the trial was approximately 28 weeks for each individual participant, including the follow-up. the participants received cebranopadol for a maximum of approximately 26 weeks.

Eligibility criteria:
inclusion criteria: * informed consent signed indicating that the participant understands the purpose of and procedures required for the trial and is willing to participate in the trial. * participants must be at least 18 years of age at the enrollment visit. * women of childbearing potential must have a negative pregnancy test at enrollment and must not be lactating at the enrollment visit. * participants must be willing to use medically acceptable and highly effective methods of birth control. * participants who have completed treatment in kf6005/07 and are still in need of around-the-clock pain analgesia with strong opioids. exclusion criteria: * the participant has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments. * known to or suspected of not being able to comply with the protocol and the use of cebranopadol. * participants taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment. * history of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, bradycardia). * concurrent participation in another trial (except participation in kf6005/07) or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial, or previous participation in this trial. * employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.

Keywords: cancer-related pain cebranopadol
validation study of the korean version of the eortc qlq-hdc29

Conditions: Quality of Life After Stem Cell Transplantation

Summary: the aim of this study is to evaluate the reliability and validity of the korean version of the european organization for research and treatment of cancer high-dose chemotherapy module (eortc hdc-29).


Eligibility criteria:
inclusion criteria: * patients who are aged more than 18 years * patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (sct) * patients who agree with the informed consent exclusion criteria: * patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity
posturography-assisted vestibular retraining for stable unilateral vestibular deficit

Conditions: Dizziness; Equilibrium; Disorder, Labyrinth; Inner Ear Injury; Inner Ear Disease

Summary: people that have difficulty with balance have a higher risk of falling and reduced quality of life. some individuals can learn to compensate using their vision, their sense of where their limbs are in space, and balance organs that are still intact. rehabilitation exercises, which typically involve shaking and nodding of the head, are often prescribed for dizzy patients but are not effective for everyone. our study aims to determine if specific exercises performed on footplate sensors with visual feedback is superior to traditional rehabilitation exercises done at home for improving balance and quality of life.


Eligibility criteria:
inclusion criteria: * dizziness handicap inventory score at time of enrolment over 30 * unilateral vestibular weakness confirmed one or more of: * videonystagmography showing unilateral weakness to bithermal testing of greater than 25% * vemp: iad asymmetry of greater than 40% for both cvemp and ovemp * vemp: absence of both ocular and cervical vemp responses in one ear in the context of normal and replicable other ear * or unilateral vestibular weakness idiopathic, not yet diagnosed (nyd) * persistent imbalance following diagnosis of resolved benign paroxysmal positional vertigo (bppv) * symptomatic * long-standing/persistent symptoms greater than six months exclusion criteria: * orthopedic deficit (eg. lower body joint dysfunction or lower joint replacement) * neurological deficit or proprioception deficit * diabetes * poor vision or blindness * fluctuating vestibular symptoms, or condition known to fluctuate eg. menière's disease, perilymphatic fistula (plf) or superior canal dehiscence (sdcs) * active benign paroxysmal positional vertigo (bppv) * undergoing treatment which may affect balance or ability to stand * cognitive impairment that prevents understanding and responding to instructions required to complete the study * inability to provide informed consent